Author

O. C. Lingjaerde

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A.-L. Borresen-Dale· 2 shared F. Markowetz· 2 shared A. Helland· 1 shared A. Hurtado-Rodriguez· 1 shared A. M. Leroi· 1 shared A. Saetersdal· 1 shared A. Trinh· 1 shared A.-M. Fosdahl· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A.-L. Borresen-Dale

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1

S. Gilfillan, S. Wang, M. R. Katika, J. H. Norum, H. Bergholtz, E. Fiorito, S. Nordhagen, Y. Sharma, S. Singh, V. S. Somisety, A.-M. Fosdahl, S. Nord, O. Engebraaten, O. C. Lingjaerde, A.-L. Borresen-Dale, , A. Hurtado-Rodriguez

This study shows that HER2/HER3 signaling and FOXA1 deacetylation drive ER-independent growth in hormone-resistant breast tumors by altering FOXA1 chromatin binding and function.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology

Neutral tumor evolution?

M. Tarabichi, I. Martincorena, M. Gerstung, A. M. Leroi, F. Markowetz, P. T. Spellman, Q. D. Morris, O. C. Lingjaerde, D. C. Wedge, P. Van Loo, PCAWG Evolution and Heterogeneity Working Group

The paper explores tumor evolution through subclonal analysis and discusses the role of driver and passenger mutations in cancer progression.

bioRxiv · Jul 23, 2018Cancer Biology

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors

I. H. Rye, A. Trinh, A. Saetersdal, D. Nebdal, O. C. Lingjaerde, V. Almendro, K. Polyak, A.-L. Borresen-Dale, A. Helland, F. Markowetz, H. G. Russnes

This study examines how intra-tumor heterogeneity in HER2 expression and copy number affects treatment outcomes in HER2+ breast cancer patients.

bioRxiv · Apr 18, 2018Cancer Biology